It’s been a wild 12 months for Moderna (MRNA), the drugmaker who’s been smack dab in the center of the COVID-19 vaccine conversation since last spring.
Shortly after Pfizer (PFE) and BioNTech (BNTX) debuted their vaccine in early December, Moderna came to market a week later, and still remains one of the only two vaccines approved in the U.S. to help prevent infection of COVID-19.
Despite the fact that Moderna is only one of two options to combat the pandemic in the U.S., shares of the drugmaker’s stock have been on quite the roller coaster ride over the past few months. As of Wednesday, shares of Moderna were more than 22% lower than their all-time highs set just about two weeks ago.
But, since then the company’s stock has been trending up again, currently riding a 5% rally from its Wednesday low… all on the heels of news that has nothing to do with COVID-19, according to CNBC.’s Jim Cramer who revealed Moderna is nearing the development of a vaccine that could protect against certain forms of cancer:
“This is not an RNA messenger vaccine company for COVID. This is a new way to be able to stop diseases and people I know that are working with this company know that they may have a vaccine against certain forms of cancer. That’s how powerful RNA messenger is. I’ve been reluctant to say that but I have it from more than one source. I have it from two sources, both of whom are involved … and it’s just incredible. We’re taking about a Noble Prize. It works.”
“Noble Prize” is about as much hype as you can pump into a story about a potential cancer vaccine. If reports from Cramer’s sources are accurate, this could be a massive breakthrough for Moderna and a potential juggernaut in the world of drug stocks.